Drugs / leridistim
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00004215 | Aug 1999 → Aug 2000 | anemia, leukemia, neutropenia, thrombocytopenia | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | leridistim | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00004215 ↗ |
| Known as | SC-70935 | “Clinical Protocol for a Phase II Study of Leridistim (SC-70935) in Adult Patients (Age>55) With Acute Myeloid Leukemia (AML) Receiving Chemotherapy With the Cytarabine and...” NCT00004215 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL2108421 ↗ |
| Route | Subcutaneous | “Patients receive leridistim subcutaneously (SQ) every other day” NCT00004215 ↗ |